High blood pressure is widely recognised as a major risk factor for heart disease and cerebrovascular accident. Now, scientists have discovered that it may also contribute to the deterioration of joints affected by osteoarthritis.

A study published in Science has identified a previously unexplained biological connection between hypertension and cartilage damage. The findings suggest that a hormone produced in the brain can trigger destructive changes inside vulnerable joints, potentially opening the door to new treatments.

Why Osteoarthritis Matters

Osteoarthritis is a common joint condition characterised by the gradual breakdown of cartilage, the protective tissue covering the ends of bones.

As cartilage deteriorates, patients may experience pain, stiffness, swelling and reduced mobility. The knees are particularly vulnerable, although the condition can affect several joints.

An estimated 595 million people worldwide were living with osteoarthritis in 2020, with cases increasing substantially over recent decades.

Ageing, previous injuries and excess body weight are established risk factors. However, scientists are increasingly investigating how metabolic and cardiovascular conditions might influence disease progression.

The Connection With Blood Pressure

Researchers analysed health information from 36,820 South Korean adults aged 45 and older.

They found an association between hypertension and osteoarthritis, with stronger links among participants showing more severe knee damage.

To investigate the possible mechanism, scientists conducted experiments involving mice with elevated blood pressure and experimentally induced joint injuries.

The results indicated that hypertension could accelerate cartilage deterioration in joints already affected by ageing or mechanical damage.

These findings suggest that blood pressure may influence joint health through biological processes extending beyond ordinary mechanical stress.

How A Brain Hormone Damages Cartilage

The researchers identified arginine vasopressin, or AVP, as a central component of the process.

This hormone helps regulate the body's water balance and blood pressure. In the experimental models, hypertension was associated with increased circulating AVP.

The hormone entered joint fluid, where it encountered a receptor called AVPR1A.

Healthy cartilage generally contains little of this receptor. However, ageing or injury can increase its presence, making damaged joints more responsive to the hormone.

When AVP binds to AVPR1A, it activates a molecular pathway involving the gene regulator NR4A3.

This encourages cartilage cells to produce destructive enzymes while reducing essential structural components, including collagen and aggrecan.

What The Scientists Discovered

Researchers also examined human cartilage and joint fluid collected during knee replacement operations.

Damaged tissue showed increased levels of AVPR1A, supporting the relevance of the pathway identified in animals.

Study author Su-Jin Kim and colleagues explained that the newly identified hormonal signalling mechanism could offer a potential therapeutic target for protecting vulnerable joints from hypertension-associated damage.

In mouse experiments, removing the AVPR1A gene prevented hypertension from accelerating cartilage deterioration.

Injecting relcovaptan, a drug that blocks vasopressin receptors, directly into affected joints produced a similar protective effect.

Interestingly, conventional blood pressure medication did not prevent cartilage damage in the experimental models.

Could This Lead To New Treatments?

The findings raise the possibility of developing treatments that specifically interrupt harmful hormonal signalling inside joints.

However, the research remains at an early stage. The protective effects of relcovaptan were demonstrated in mice, and its effectiveness for human osteoarthritis has yet to be established.

The population findings also demonstrate an association rather than proving that hypertension directly causes osteoarthritis in people.

Importantly, patients should continue taking prescribed blood pressure medication. Controlling hypertension remains essential for cardiovascular health.

Further research must establish whether targeting AVPR1A can safely slow cartilage deterioration in humans.

For now, the discovery provides a promising explanation for how cardiovascular health and joint disease may be connected, bringing scientists closer to understanding the complex biological processes behind osteoarthritis.